Clinical trial
Heart Failure and Anemia
NCT00049985 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00049985 |
|---|---|
| Title | Heart Failure and Anemia |
| Official title | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance in Subjects With Symptomatic Heart Failure (CHF) and Anemia. |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Heart Failure, Anemia |
| Intervention type | Drug |
| Interventions | Darbepoetin Alfa |
| Enrollment | 300 |
| Start date | Jul 1, 2002 |
| First posted | Nov 19, 2002 |
| Last update posted | Aug 7, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: